Pronethalol

Pronethalol
Clinical data
Trade namesAlderlin
Other namesNethalide; Pronetalol; Naphthylisoproterenol; ICI-38174; ICI38174; Compound 38174; AY-6204; AY6204
Routes of
administration
Oral
Drug classBeta blocker
ATC code
  • None
Legal status
Legal status
  • Withdrawn
Identifiers
  • 1-(naphthalen-2-yl)-2-(propan-2-ylamino)ethanol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H19NO
Molar mass229.323 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • CC(C)NCC(C1=CC2=CC=CC=C2C=C1)O
  • InChI=1S/C15H19NO/c1-11(2)16-10-15(17)14-8-7-12-5-3-4-6-13(12)9-14/h3-9,11,15-17H,10H2,1-2H3
  • Key:HRSANNODOVBCST-UHFFFAOYSA-N

Pronethalol, sold under the brand name Alderlin, was an early non-selective beta blocker. It was the first beta blocker to be developed by James Black and associates at Imperial Chemical Industries, and the first to enter clinical use, in November 1963.

However, it was never used widely due to carcinogenicity in mice, which was thought to result from formation of a carcinogenic naphthalene epoxide metabolite, and was superseded by propranolol from 1965 onward.